Chinese biotech company Akeso is emerging as a major challenger in the global cancer drug market after clinical trial results showed its lung cancer treatment outperformed Merck’s Keytruda, one of the world’s best-selling medicines.
The drug, ivonescimab, uses a bispecific antibody approach to target two biological pathways linked to cancer: PD-1, which suppresses immune response, and VEGF, which supports blood vessel growth around tumors. A trial in China showed the treatment extended control of lung cancer compared with Keytruda.
A global Phase 3 study led by Akeso’s US partner, Summit Therapeutics, has also produced preliminary positive results. The treatment is being tested in patients in the US and Europe, while the US Food and Drug Administration is reviewing an application for approval in one type of lung cancer.
Founded in 2012 by Michelle Xia and three scientists educated overseas, Akeso raised $3M in early funding and has grown from a 20-square-metre office into a company with around 4,500 employees. It listed in Hong Kong in 2020 and reported revenue of more than 3B yuan, or about $400M, in 2025.
Akeso now has eight marketed medicines in China and more than 50 drug candidates under development. In late 2022, it granted Summit development and commercialisation rights for ivonescimab in the US and other global markets in a deal potentially worth up to $5B, according to the report.
Source: Al Arabiya


